Gene expression using T cell factor responsive element
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Feb 20, 2007
Grant Date -
Mar 11, 2004
app pub date -
Jun 26, 2003
filing date -
Mar 2, 2000
priority date (Note) -
Expired
status (Latency Note)
Importance
Abstract
Disclosed are DNA elements and constructs useful for obtaining tumor-selective gene expression in tumors having a mutated .beta.-catenin/APC pathway. In particular, the use of these constructs to express genes encoding therapeutic proteins in colorectal cancer cells is described. The constructs comprise multiple repeats of a TCF-binding element operably linked to a promoter. By means of such a construct, tumor cell-specific expression of a prodrug-converting enzyme such as nitroreductase may be achieved. Coupled with systemic administration of a suitable prodrug, such as CB1954, selective killing of such tumor cells can be demonstrated.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully